• / Free eNewsletters & Magazine
  • / My Account
Home>Valeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon

Valeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon

3party Content

Fri, 30 Jan 2015

By Jonathan D. Rockoff Valeant Pharmaceuticals International Inc. said late Thursday it has reached a tentative deal to buy the prostate-cancer drug Provenge and other assets from Dendreon Corp. for $296 million in cash. Quebec-based Valeant said it has entered into a so-called stalking-horse
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.